India-based Cipla has partnered with UK’s S&D Pharma to launch affordable, high-quality alternatives in the Czech Republic and Slovakia.
Under the deal, Cipla will introduce its respiratory product portfolio in both the countries, while S&D Pharma will look after the physical distribution of all products, including respiratory products.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Cipla Europe head Frank Pieters said: "We are excited to partner with S&D Pharma and believe that this collaboration will enable us to drive access in the Czech Republic and Slovakia across therapy areas in the coming years."
S&D Pharma CEO Daniel Straus added: "Through this collaboration, we have secured a competitive and varied product pipeline for the future and very much look forward to contributing to the future success of Cipla’s respiratory range."
Cipla will launch the Salmeterol-Fluticasone fixed combination in both markets under the name Fullhale after the receipt of necessary regulatory and reimbursement approvals.
Fullhale will be available in a pMDI with HFA propellant in two strengths, 120 doses of 25/125mcg salmeterol/fluticasone and 120 doses of 25/250mcg salmeterol/fluticasone.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe combination is already available under the name Duohal in Europe, apart from Croatia.
Recently, Cipla launched this product in Germany under the name of Serroflo, while in Sweden as Salmeterol/Fluticasone Cipla.
Cipla produces around 2000 products in 65 therapeutic categories and has presence in about 170 countries, while S&D Pharma manages the promotion and distribution of their products in Central Europe.
